Skip to content
Inciteful Med

The Biggest Risk: AA Amyloidosis and Protecting Your Kidneys

Last updated:

AA amyloidosis is a serious but highly preventable complication of Familial Mediterranean Fever (FMF) that can cause permanent kidney damage. Taking colchicine daily suppresses the silent inflammation that causes amyloid proteins to build up and protects your kidneys.

Key Takeaways

  • • AA amyloidosis is a serious complication of Familial Mediterranean Fever that can lead to permanent kidney damage.
  • • Early kidney damage often has no visible symptoms, making routine urine tests for protein essential.
  • • Taking colchicine every day is the most effective way to prevent amyloidosis and protect your kidney function.
  • • Patients with the M694V genetic mutation or a history of delayed diagnosis face a higher risk for kidney involvement.
  • • Uncontrolled "silent" inflammation can cause organ damage even during periods when you are not experiencing painful FMF attacks.

The most serious concern for anyone living with Familial Mediterranean Fever (FMF) is a condition called AA amyloidosis [1]. While the “attacks” of FMF are painful and disruptive, amyloidosis is a “silent” complication that can lead to permanent kidney damage if the underlying inflammation is not kept under strict control [2][3].

What is AA Amyloidosis?

When your body experiences the frequent or “silent” inflammation of FMF, your liver produces high levels of a protein called Serum Amyloid A (SAA) [1][4].

  • The Buildup: If SAA levels stay high for a long time, the protein can begin to fold incorrectly, creating hard, insoluble clumps called amyloid fibrils [1].
  • The Damage: These fibrils act like “sand” in the gears of your organs. They primarily settle in the kidneys, where they slowly interfere with the organ’s ability to filter waste from your blood [2][5].

How the Kidneys are Affected

Kidney damage from amyloidosis usually follows a predictable path. Catching it at the earliest stage is vital for protecting your health [2].

  1. Microalbuminuria (Early Warning): This is the very first sign. It means tiny amounts of a protein called albumin are “leaking” into your urine [2]. You won’t feel this, which is why regular urine tests are essential.
  2. Proteinuria: As damage progresses, larger amounts of protein leak out. You might notice that your urine looks unusually foamy [2][3].
  3. Nephrotic Syndrome: This occurs when protein loss is so high that your body begins to swell, typically in the ankles and legs (called edema) [2][6].
  4. Kidney Failure: If left untreated, the kidneys can eventually stop working altogether, leading to the need for dialysis or a kidney transplant [2][7].

Your “Shield”: Colchicine and Monitoring

The good news is that AA amyloidosis is highly preventable [8][9].

  • The Power of Daily Treatment: Taking colchicine every single day is your most powerful defense. It stabilizes your immune system and lowers the production of SAA, preventing the “sand” from forming in the first place [10][2].
  • Checking for “Silent” Inflammation: Even if you aren’t having painful attacks, your body might still be making too much SAA [11][12]. Your doctor may test your SAA levels or CRP during your “well” periods to make sure your dose of colchicine is high enough to protect your kidneys [2][1].
  • Urine Screening: A simple urine test every 6 to 12 months can catch microalbuminuria long before it becomes a serious problem [2].

Risk Factors to Discuss with Your Doctor

Some people are at a higher risk for amyloidosis and may need more frequent monitoring:

  • Genetics: Patients with two copies of the M694V mutation are often at a higher risk for kidney involvement [13][14].
  • Diagnostic Delay: Those who went many years without a diagnosis before starting treatment have a higher risk of existing protein buildup [15].
  • Colchicine Resistance: If you continue to have frequent attacks despite taking colchicine, your doctor may recommend switching to IL-1 inhibitors to ensure your SAA levels are properly lowered [16][17].

By staying consistent with your medication and regular check-ups, you can effectively “lock the door” against amyloidosis and keep your kidneys healthy for life [8][18].

Frequently Asked Questions

What is AA amyloidosis in FMF?
AA amyloidosis is a condition where chronic inflammation from FMF causes an abnormal protein called amyloid to build up in your organs. This buildup acts like sand in the gears of your kidneys, potentially leading to kidney failure if left untreated.
How do I know if FMF is damaging my kidneys?
Early kidney damage from amyloidosis usually has no visible symptoms, which is why regular urine tests are crucial to check for microscopic protein leaks. As damage progresses, you might notice unusually foamy urine or swelling in your legs and ankles.
Can AA amyloidosis be prevented?
Yes, AA amyloidosis is highly preventable. Taking colchicine every single day stabilizes your immune system and stops the production of the proteins that cause amyloid buildup, effectively protecting your kidneys.
Does the M694V mutation increase my risk for kidney damage?
Patients with two copies of the M694V genetic mutation have a higher risk of developing kidney involvement. If you carry this mutation, your doctor will likely monitor your kidney health and inflammation markers more frequently.
Why do I need to take colchicine even when I feel healthy?
Even without painful attacks, your body may still experience "silent" inflammation that produces dangerous proteins. Taking colchicine daily suppresses this underlying inflammation and shields your kidneys from irreversible damage.

Questions for Your Doctor

  • • What is my most recent microalbuminuria (urine protein) result, and how often should we be testing for it?
  • • Since I have the [specific variant, e.g., M694V] mutation, am I at a higher risk for AA amyloidosis than other patients?
  • • Can we check my Serum Amyloid A (SAA) levels during an 'attack-free' period to see if I have silent inflammation?
  • • If we find protein in my urine, at what point should we consider adding an IL-1 blocker to my colchicine treatment?
  • • Are my blood pressure and kidney function (eGFR) within the healthy range for my age?

Questions for You

  • • Do I take my colchicine every single day, even when I feel completely healthy?
  • • Have I noticed any new swelling in my ankles or legs (edema), or does my urine ever look unusually foamy?
  • • Do I have any relatives with FMF who had kidney failure or required dialysis?
  • • How long did I have symptoms before I was officially diagnosed and started on treatment?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    French practical guidelines for the diagnosis and management of AA amyloidosis.

    Georgin-Lavialle S, Savey L, Buob D, et al.

    La Revue de medecine interne 2023; (44(2)):62-71 doi:10.1016/j.revmed.2022.12.004.

    PMID: 36759076
  2. 2

    Amyloidosis and Glomerular Diseases in Familial Mediterranean Fever.

    Siligato R, Gembillo G, Calabrese V, et al.

    Medicina (Kaunas, Lithuania) 2021; (57(10)) doi:10.3390/medicina57101049.

    PMID: 34684086
  3. 3

    Familial Mediterranean fever-associated renal amyloidosis: case report and review of the literature.

    Andronesi AG, Ismail G, Gherghiceanu M, et al.

    Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 2019; (60(4)):1299-1303.

    PMID: 32239108
  4. 4

    Secondary amyloidosis associated with heroin use and recurrent infections - A case report.

    Mani D

    Annals of medicine and surgery (2012) 2019; (37()):38-41 doi:10.1016/j.amsu.2018.11.013.

    PMID: 30581568
  5. 5

    Familial Mediterranean Fever-Related Amyloidosis in Turkey: A Need for a Familial Mediterranean Fever Registry.

    Helvaci O, Yasar E

    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 2023; (21(Suppl 2)):101-104 doi:10.6002/ect.IAHNCongress.24.

    PMID: 37496356
  6. 6

    Profile of renal AA amyloidosis in older and younger individuals: a single-centre experience.

    Erdogmus S, Kendi Celebi Z, Akturk S, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2018; (25(2)):115-119 doi:10.1080/13506129.2018.1474733.

    PMID: 29775082
  7. 7

    The M694I/M694I genotype: A genetic risk factor of AA-amyloidosis in a group of Algerian patients with familial Mediterranean fever.

    Ait-Idir D, Djerdjouri B, Bouldjennet F, et al.

    European journal of medical genetics 2017; (60(3)):149-153 doi:10.1016/j.ejmg.2016.12.003.

    PMID: 27956278
  8. 8

    Familial Mediterranean Fever.

    Ozdogan H, Ugurlu S

    Presse medicale (Paris, France : 1983) 2019; (48(1 Pt 2)):e61-e76 doi:10.1016/j.lpm.2018.08.014.

    PMID: 30686512
  9. 9

    [Familial mediterranean fever].

    Vinit C

    La Revue du praticien 2023; (73(8)):843-849.

    PMID: 38354004
  10. 10

    Familial Mediterranean Fever: Recent Developments in Pathogenesis and New Recommendations for Management.

    Özen S, Batu ED, Demir S

    Frontiers in immunology 2017; (8()):253 doi:10.3389/fimmu.2017.00253.

    PMID: 28386255
  11. 11

    Serum Amyloid A Level in Egyptian Children with Familial Mediterranean Fever.

    Lofty HM, Marzouk H, Farag Y, et al.

    International journal of rheumatology 2016; (2016()):7354018 doi:10.1155/2016/7354018.

    PMID: 28070191
  12. 12

    Outcomes of Canakinumab Treatment in Recipients of Kidney Transplant With Familial Mediterranean Fever: A Case Series.

    Sendogan DO, Saritas H, Kumru G, et al.

    Transplantation proceedings 2019; (51(7)):2292-2294 doi:10.1016/j.transproceed.2019.03.049.

    PMID: 31400972
  13. 13

    Mutational Spectrum of the MEFV Gene in AA Amyloidosis Associated With Familial Mediterranean Fever.

    Nursal AF, Tekcan A, Kaya SU, et al.

    Iranian journal of kidney diseases 2016; (10(3)):107-12.

    PMID: 27225717
  14. 14

    Predicting genetic risk factors for AA amyloidosis in Algerian patients with familial Mediterranean fever.

    Ait-Idir D, Djerdjouri B, Latreche K, et al.

    Molecular genetics and genomics : MGG 2024; (299(1)):25 doi:10.1007/s00438-024-02133-6.

    PMID: 38451362
  15. 15

    Diagnostic delays in familial Mediterranean fever: a Juvenile Inflammatory Rheumatism (JIR) cohort study.

    Bourguiba R, Deshayes S, Amaryan G, et al.

    Rheumatology international 2024; (44(12)):3107-3111 doi:10.1007/s00296-024-05706-1.

    PMID: 39316109
  16. 16

    Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review

    Tufan A, Lachmann HJ

    Turkish journal of medical sciences 2020; (50(SI-2)):1591-1610 doi:10.3906/sag-2008-11.

    PMID: 32806879
  17. 17

    The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review.

    Hentgen V, Vinit C, Fayand A, Georgin-Lavialle S

    Frontiers in immunology 2020; (11()):971 doi:10.3389/fimmu.2020.00971.

    PMID: 32670263
  18. 18

    Non-adherence to colchicine treatment is a common misevaluation in familial Mediterranean fever

    Tekgöz E, Çolak S, Çınar Fİ, et al.

    Turkish journal of medical sciences 2021; (51(5)):2357-2363 doi:10.3906/sag-2102-328.

    PMID: 33957721

This page provides educational information about AA amyloidosis risk in FMF. It is not medical advice. Always consult your rheumatologist or nephrologist regarding your kidney function, test results, and treatment plan.

Stay up to date

Get notified when new research about Familial Mediterranean fever is published.

No spam. Unsubscribe anytime.